44 results about "Blood clotting factors" patented technology

Compounds of formula (I)as factor VII-tissue factor inhibitors as well as novel benzoxazin derivatives are disclosed, wherein R1, R2, R3, X and Y are as defined in the specification. These compounds, and pharmaceutically acceptable salts thereof, have been shown to be inhibitors of factor VIIa-tissue factor activity and have anticoagulant properties. These compounds are useful for treating deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors. Methods for inhibiting clotting activity are also disclosed.

Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and deeply inhaled into the lung, and followed by a maximal exhale.

The invention relates to the use of a Factor VIIa-related polypeptide for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, in particular a bleeding episode, said medicament being for subcataneous or intramuscular administration.

The invention provides materials and methods for modulating adenoviral tropism for hepatocytes and other cell types such as splenocytes. It relates to the findings that hypervariable regions (HVRs) of the viral hexon protein interact with the Gla domain of the blood clotting factor FX as part of the infective process in vivo. The invention provides means to disrupt the interaction between hexon and FX, thus reducing infection of hepatocytes and splenocytes, as well as use of targeting agents comprising the Gla domain or a fragment thereof to direct adenoviral vectors to desired target cell or tissue types.

The present invention provides methods and compositions for treating blood clotting factor disorders and/or reducing bleeding-associated joint damage by treatments delivered to the joint in a subject.

The invention discloses a reagent for screening and determining lupus anticoagulant (LA) in blood plasma by a dilution viper venom test method. The LA screening and determining reagent comprises viper venom blood clotting factor X activating agents, rapeseed phosphatide and calcium ions. The rapeseed phosphatide replaces the animal cephalin in the prior art, the proper addition quantity is low, and the rapeseed phosphatide has higher specificity and sensitivity for LA. The LA screening and determining reagent has the advantages of good specificity, high sensitivity, high stability and high detection feasibility degree.

The invention relates to a preparation method of a clinical blood coagulation inspection preparation and particularly relates to a preparation method of a blood coagulation factor IX quality control product. The preparation method comprises the following steps: carrying out affinity chromatography on the mixed blood plasma of multiple persons by using an anti-human blood coagulation factor IX monoclonal antibody immunoaffinity chromatography column, removing a blood coagulation factor IX in the mixed blood plasma of multiple persons to obtain a blood plasma in shortage of the blood coagulation factor IX; mixing the mixed blood plasma of multiple persons with the blood plasma in shortage of the blood coagulation factor IX according to a certain proportion to prepare a blood coagulation factor IX quality control product with the content of the blood coagulation factor IX at different concentration levels, adding a freeze-drying protective additive, carrying out sub-packaging, and carrying out freeze drying so as to obtain the blood coagulation factor IX quality control product. According to the blood coagulation factor IX quality control product prepared by the preparation method, the uniformity, the stability and the stability of freeze-dried aquatic product subjected to re-melting are good, and the quality control product can replace an imported product to be used for quality control on detection of blood coagulation factor IX, so that the reduction of the detection cost is facilitated and the capability of detecting the blood coagulation factor IX in China can be promoted.

Monoclonal antibodies directed against coagulation factor IX and their use in inhibiting thrombosis are disclosed.

The invention relates to a stabilizing agent for preventing blood clotting factor reactive loss for prothrombin composite or blood clotting factor IX preparation during virus animatum eradication by dry heat, wherein the stabilizing agent is sucrose or / and arginine or its salt, it also can contain one or more of the conventional glycine, NaCl, citric acid trisodium and hamocura.

The invention relates to mRNA therapy for the treatment of Hemophilia A. mRNAs for use in the invention, when administered in vivo, encode Factor VIII, isoforms thereof, functional fragments thereof, and fusion proteins comprising Factor VIII. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Factor VIII expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient Factor VII I activity in subjects.

The invention relates to anticoagulant polypeptide and an application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID NO.2. Anticoagulation is an endogenous blood coagulation resisting pathway, and the endogenous blood coagulation pathway is a blood coagulation effect participated or mediated by a blood coagulation factor XIa (FXIa). The invention also relates to a nucleotide sequence for encoding the anticoagulant polypeptide, and the nucleotide sequence is shown as SEQ ID NO.1. The invention also relates to an application of the anticoagulant polypeptide.

The present invention relates to the field of therapeutic proteins, in particular, to recombinant coagulation factors. It provides a recombinant Factor VIII (FVIII) protein comprising specific point mutations at defined positions, which serve to reduce the immunogenicity of said FVIII protein, wherein the Factor VIII protein substantially retains its coagulant activity. The invention further provides nucleic acids encoding said de-immunized protein, cell lines and methods of recombinant preparation as well as pharmaceutical compositions comprising the recombinant FVIII of the invention, whichare advantageous for use in treatment of patients with Hemophilia A, particularly those who have not yet been treated with a FVIII product. Additionally, it can be a safe alternative for previously treated patients and even for patients who have developed an immune-response to FVIII, e.g., for immune-tolerance-induction therapy (ITI/ITT) or rescue ITI. The invention also provides an assay for determining immunogenicity of a protein.

The invention provides application of a urine coagulation factor IX and a polypeptide fragment of the urine coagulation factor IX, and particularly relates to application of the urine coagulation factor IX and the polypeptide fragment of the urine coagulation factor IX in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. Burns are common important wounds in daily life, about 5000-100000 people in every one million people are burnt every year, according to statistics of World Health Organization, more than 300,000 people die from burn patients globally every year, and the treatment survival rate of serious burns is still at a lower level. Researches prove that compared with healthy people (a normal control group), the expression of the urine blood coagulation factor IX and the polypeptide fragment thereof in burn patients is increased, and the content of the urine blood coagulation factor IX and the polypeptide fragment thereof is gradually increased along with the aggravation of the burn degree. The method can be used for various purposes of application detection of burn patients. The advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and the urine blood coagulation factor IX and the polypeptide fragment thereof are detected by utilizing the urine sample.

The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.

The invention relates to methods for the treatment of a severely bleeding subject.

The embodiment of the invention discloses a method for purifying a blood coagulation factor VII. The method comprises the following steps: degreasing rabbit milk of a blood coagulation factor VII transgenic rabbit to obtain degreased rabbit milk; the degreased rabbit milk is subjected to SP Fast Flow cation chromatography, and a first purified solution containing the blood coagulation factor VII is obtained; carrying out chromatography on the first purified liquid by virtue of a Heparin Bestarose HP chromatographic column, so as to obtain a second purified liquid containing the blood coagulation factor VII; and carrying out Butyl-650M chromatography on the second purified liquid to obtain a third purified liquid containing the blood coagulation factor VII. According to the method for purifying the blood coagulation factor VII, the blood coagulation factor VII is subjected to crude purification by using an SP Fast Flow filler so as to remove most of impure proteins in rabbit milk, then an SP Fast Flow elution sample is purified by using a Heparin Bestarose HP chromatographic column, and finally the Heparin Bestarose HP elution sample is purified by using Butyl-650M chromatography, so that the blood coagulation factor VII is purified. Therefore, the influence of a large amount of casein in the rabbit milk on the affinity filler loading capacity and the purification effect is reduced, the blood coagulation factor purity can be effectively improved, the cost is reduced, and the economic benefit is improved.